Showing results (201-210 of 244) with videos related to

Sort By:
Pageof 25
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 16, 2026
Identification, structural elucidation and nonclinical characterization of oxMET1: A further major metabolite of xevinapant?Benedikt Lang, Hanno Schieferstein, Holger Scheible, et al.
Bioorganic & Medicinal Chemistry Letters|April 7, 2025
Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non‑zinc binding modeRainer E Martin, Alexander L Satz, Christoph Kuratli, et al.
Nature Communications|January 31, 2020
Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancerKatharina von Loga, Andrew Woolston, Marco Punta, et al.
Nature Communications|January 18, 2020
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancerKatharina von Loga, Andrew Woolston, Marco Punta, et al.
Anticancer Research|May 18, 2012
Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myelomaLisa Billecke, Eva Maria Murga Penas, Annette M May, et al.
Antioxidants & Redox Signaling|September 29, 2015
Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+Stefan Schildknecht, Regina Pape, Johannes Meiser, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 2014
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantationTim Luetkens, Sebastian Kobold, Yanran Cao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 5, 2006
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagusUta Reichelt, Peer Duesedau, Maria Ch Tsourlakis, et al.
Clinical & Developmental Immunology|December 23, 2011
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantationSebastian Kobold, Sinje Tams, Tim Luetkens, et al.
Pageof 25